Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Peter Singleton who wrote (4998)	7/25/1998 6:19:00 PM
From: Izzy	Read Replies (1) of 6136

MS analysis (7-22-98) "The New Agouron" [6 page report]: FISCAL 1999 Viracept US sales: $430-440 million Hoffmann-La Roche royalties: $30-35 million Contract revenues: $35-40 million Gross margins: 69-73% Royalty payments to Japan Tobacco: 24-25% US Viracept sales European sales: $240 million ($29 million to AGPH) FISCAL 2000 Viracept US sales: $512 million European sales (thru 2002): $450-460 million REMUNE Fiscal 2001: $160 million 2004: $400 million (30% virtual royalty to IMNR)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next